Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel plus prednisone vs placebo plus prednisone in metastatic castration-resistant prostate cancer post-docetaxel
CTR20131423Phase 3Completed
- Sponsor
- IgGenix
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orteronel in prostate cancer (PCa), sponsored by IgGenix. Started Apr 2014; status: completed.
02
Drugs
orteronel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20131423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131423.